Oversight of medical software

FDA Releases Artificial Intelligence/Machine Learning Action Plan

The U.S. Food and Drug Administration released the agency’s first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency’s oversight of AI/ML-based medical software.

“This action plan outlines the FDA’s next steps towards furthering oversight for AI/ML-based SaMD,” said Bakul Patel, director of the Digital Health Center of Excellence in the Center for Devices and Radiological Health (CDRH). “The plan outlines a holistic approach based on total product lifecycle oversight to further the enormous potential that these technologies have to improve patient care while delivering safe and effective software functionality that improves the quality of care that patients receive. To stay current and address patient safety and improve access to these promising technologies, we anticipate that this action plan will continue to evolve over time.”

More details on the FDA website.

13.01.2021

Related articles

Photo

Article • Technology overview and outlook

AI in healthcare: Significant potential – and serious obstacles

Sure, AI still has a long way go. But maybe one day in the not-so-distant future, AI will provide us with information about our current state of health, such as the number of red blood cells,…

Photo

News • Discerning good algorithms from bad ones

Medical AI evaluation is surprisingly patchy, study finds

In just the last two years, artificial intelligence has become embedded in scores of medical devices that offer advice to ER doctors, cardiologists, oncologists, and countless other health care…

Photo

Interview • Diagnostics & therapy

AI: Hype, hope and reality

Artificial intelligence (AI) opens up a host of new diagnostic methods and treatments. Almost daily we read about physicians, researchers or companies that are developing an AI system to identify…

Related products

Subscribe to Newsletter